Shom Goel
Has grant
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Open
Enhancing the benefits of CDK inhibition in breast cancer
Open Date: 2026-10-01
Close Date: 2027-09-30
Grant: Close
Enhancing the benefits of CDK inhibitors in breast cancer
Open Date: 2024-10-01
Close Date: 2025-09-30
Articles (27)
Purpose: Cyclin-dependent kinase 4/6 inhibitors can significantly extend survival when given in combination with endocrine therapy in patients with hormone receptor–positive metastatic breast cancer. However, their activity has been relatively underexplored in patients with metastatic triple-negative breast cancer (mTNBC). Patients and Methods: We conducted a single-arm phase II study of abemaciclib monotherapy in patients with Rb-positive mTNBC. Patients were treated with abemaciclib 200 mg orally twice daily until disease progression, unacceptable toxicity, or withdrawal of consent. The primary endpoint was the objective response rate; secondary endpoints included progression-free survival (PFS), overall survival (OS), clinical benefit rate, disease control rate, and safety and tolerability. Results: A total of 27 patients were enrolled before the trial was closed early because of slow accrual. Patients had received a median of two lines of systemic therapy in the metastatic setting prior to enrollment. After a median follow-up of 28.5 months, the objective response rate was 0%, the clinical benefit rate was 14.8%, and the disease control rate was 22.2%. The median PFS was 1.94 months (95% confidence interval, 1.84–11.47), and the median OS was 8.44 months (95% confidence interval, 4.57–15.57). Median PFS and OS did not differ significantly based on androgen receptor and PD-L1 status. Pretreatment gene expression profiling of tumor tissue provided some hypothesis-generating insights into biological features associated with clinical benefit in this study. The most common treatment-related adverse events of grade 2 or higher were diarrhea (40.7%), neutropenia (40.7%), anemia (29.6%), and nausea (29.6%). Conclusions: Abemaciclib monotherapy did not show clinical activity in patients with pretreated Rb-positive mTNBC.
Year:
2025
Background Preclinical evidence suggests that cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors enhance antitumor immunity. We conducted a phase I trial of ribociclib (CDK4/6 inhibitor) plus spartalizumab (PD-1 inhibitor) in patients with hormone receptor (HR)-positive/HER2-negative metastatic breast cancer (MBC) or advanced ovarian cancer (AOC). The combination was also evaluated with fulvestrant in MBC. Methods In Cohort A, ribociclib was administered on Days 1–21 (28-day cycle) starting at 400 mg, and spartalizumab at 400 mg on Day 1. Dose escalation was followed by expansion in AOC. Fulvestrant was added (Cohort B) with a safety run-in followed by expansion in MBC. Primary objectives were to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D), and safety and tolerability of the combinations. Results 33 patients enrolled (n=18, Cohort A; n=15, Cohort B). The RP2D of ribociclib in both cohorts was 600 mg. Treatment-related adverse events in >20% of patients in either cohort were neutropenia, fatigue, anemia, thrombocytopenia, hypertransaminasemia, maculopapular rash, fatigue, and nausea. Hypertransaminasemia occurred in 66.7% (AST) and 46.7% (ALT) of patients in Cohort B, including 46.7% and 40.0%, respectively, of grade 3 or 4 events. Two confirmed partial responses were observed (13.3%) in Cohort B, in patients with low baseline serum thymidine kinase activity, coupled with an increase on-treatment. Peripheral blood flow cytometry across patients demonstrated on-target drug binding with increases in PD-1 occupancy and activated CD8 + T cells during treatment, irrespective of response. PD-L1-positivity, tumor-infiltrating lymphocytes, or tumor mutational burden did not correlate with progression-free survival (PFS). Several copy-number variations detected with next-generation sequencing correlated with PFS. Conclusions Ribociclib with spartalizumab and fulvestrant showed limited efficacy and elevated hepatotoxicity, precluding further development. Correlative analyses revealed treatment-induced immunological effects, and genomic alterations associated with PFS.
Year:
2025
Purpose: Cyclin-dependent kinase 4/6 inhibitors can significantly extend survival when given in combination with endocrine therapy in patients with hormone receptor–positive metastatic breast cancer. However, their activity has been relatively underexplored in patients with metastatic triple-negative breast cancer (mTNBC). Patients and Methods: We conducted a single-arm phase II study of abemaciclib monotherapy in patients with Rb-positive mTNBC. Patients were treated with abemaciclib 200 mg orally twice daily until disease progression, unacceptable toxicity, or withdrawal of consent. The primary endpoint was the objective response rate; secondary endpoints included progression-free survival (PFS), overall survival (OS), clinical benefit rate, disease control rate, and safety and tolerability. Results: A total of 27 patients were enrolled before the trial was closed early because of slow accrual. Patients had received a median of two lines of systemic therapy in the metastatic setting prior to enrollment. After a median follow-up of 28.5 months, the objective response rate was 0%, the clinical benefit rate was 14.8%, and the disease control rate was 22.2%. The median PFS was 1.94 months (95% confidence interval, 1.84–11.47), and the median OS was 8.44 months (95% confidence interval, 4.57–15.57). Median PFS and OS did not differ significantly based on androgen receptor and PD-L1 status. Pretreatment gene expression profiling of tumor tissue provided some hypothesis-generating insights into biological features associated with clinical benefit in this study. The most common treatment-related adverse events of grade 2 or higher were diarrhea (40.7%), neutropenia (40.7%), anemia (29.6%), and nausea (29.6%). Conclusions: Abemaciclib monotherapy did not show clinical activity in patients with pretreated Rb-positive mTNBC.
Year:
2025
Supplementary Figure 1: Characterization of INX-315.Supplementary Figure 2: Effect of INX-315 and PF-07104091 on viability of cancer and non-malignant cell lines.Supplementary Figure 3: Effect of INX-315 on cell cycle in CCNE1-amplified cancer cell lines.Supplementary Figure 4: Further characterization of the effects of INX-315 in in vitro and in vivo models of CCNE1-amplified cancer.Supplementary Figure 5: Effects of INX-315 treatment on gene expression in models of CCNE1amplified ovarian carcinoma.Supplementary Figure 6: Characterization of CDK4/6 inhibitor-resistant cell lines.Supplementary Figure 7: Response of CDK4/6 inhibitor-resistant breast cancer cells to INX-315 and PF-07104091.Supplementary Figure 8: Effects of INX-315 and PF-07104091 on CDK4/6 inhibitor-resistant breast cancer cells.Supplementary Figure 9: Impact of INX-315 +/- continued CDK4/6 inhibition in CDK4/6 inhibitorresistant breast cancer cells.Supplementary Figure 10: Characterization of a new mouse model of acquired CDK4/6 inhibitor resistance.Supplementary Figure 11: Effect of INX-315 on expression of senescence-related genes in CDK4/6 inhibitor-resistant breast cancer cells.Supplementary Figure 12: Epigenomic and transcriptomic features of INX-315 induced senescence in CDK4/6 inhibitor-resistant breast cancer.Supplementary Figure 13: Impact of INX-315 treatment of CDK4/6 inhibitor resistant breast cancer on expression of apoptosis and differentiation-related genes.Supplementary Figure 14: Impact of co-inhibition of CDK2 and CDK4/6 on cell cycle and development of CDK4/6 inhibitor resistance in breast cancer cells.
Year:
2025
Discovery and characterization of INX-315. A, Amino acid sequence homology at the ATP-binding pockets of several CDKs. B, Derivation of INX-315 through serial modifications of trilaciclib, a CDK4/6i. Table indicates biochemical IC 50 s (± SEM) to cyclin/CDK pairings shown using the Nanosyn biochemical assay. Trilaciclib IC 50 for CDK1/cyclin B1 was ND (for trilaciclib: n = 6 for CDK2/cyclin E1 and CDK2/cyclin A2, n = 9 for CDK4/cyclin D1, n = 3 for other complexes; for compound B: n = 3 for all complexes; for compound C: n = 1 for all complexes; for INX-315: if SEM is 0, n = 1, otherwise n = 6). C, Modeling of INX-315 bound to cyclin E1/CDK2. D, NanoBRET assay quantifying INX-315's intracellular displacement of tracer from the ATP-pocket of the cyclin/CDK pairings shown. Table shows calculated IC 50 s (two technical replicates per experiment, two biological replicates except for CDK2/Cyclin A1 where n = 1; error bars represent SD).BID, twice daily; QD, once daily.
Year:
2025
Year:
2024
Purpose: Triple-negative breast cancer (TNBC) is a heterogeneous disease that carries the poorest prognosis of all breast cancers. Although novel TNBC therapies in development are frequently targeted toward tumors carrying a specific genomic, transcriptomic, or protein biomarker, it is poorly understood how these biomarkers are correlated. Experimental Design: To better understand the molecular features of TNBC and their correlation with one another, we performed multimodal profiling on a cohort of 95 TNBC. Our approach involved quantifying tumor-infiltrating lymphocytes through hematoxylin and eosin staining, assessing the abundance of retinoblastoma, androgen receptor, and PDL1 proteins through IHC, and carrying out transcriptomic profiling using the NanoString BC360 platform, targeted DNA sequencing on a subset of cases, as well as evaluating associations with overall survival. Results: Levels of RB1 mRNA and RB proteins are better correlated with markers of retinoblastoma functionality than RB1 mutational status. Luminal androgen receptor tumors clustered into two groups with transcriptomes that cluster with either basal or mesenchymal tumors. Tumors classified as PDL1-positive by the presence of immune or tumor cells showed similar biological characteristics. HER2-low TNBC showed no distinct biological phenotype when compared with HER2-zero. The majority of TNBC were classified as basal or HER2-enriched by PAM50, the latter showing significantly improved overall survival. Conclusions: Our study contributes new insights into biomarker utility for identifying suitable TNBC therapies and the intercorrelations between genomic, transcriptomic, protein, and cellular biomarkers. Additionally, our rich data resource can be used by other researchers to explore the interplay between DNA, RNA, and protein biomarkers in TNBC.
Year:
2024
Purpose: Triple-negative breast cancer (TNBC) is a heterogeneous disease that carries the poorest prognosis of all breast cancers. Although novel TNBC therapies in development are frequently targeted toward tumors carrying a specific genomic, transcriptomic, or protein biomarker, it is poorly understood how these biomarkers are correlated. Experimental Design: To better understand the molecular features of TNBC and their correlation with one another, we performed multimodal profiling on a cohort of 95 TNBC. Our approach involved quantifying tumor-infiltrating lymphocytes through hematoxylin and eosin staining, assessing the abundance of retinoblastoma, androgen receptor, and PDL1 proteins through IHC, and carrying out transcriptomic profiling using the NanoString BC360 platform, targeted DNA sequencing on a subset of cases, as well as evaluating associations with overall survival. Results: Levels of RB1 mRNA and RB proteins are better correlated with markers of retinoblastoma functionality than RB1 mutational status. Luminal androgen receptor tumors clustered into two groups with transcriptomes that cluster with either basal or mesenchymal tumors. Tumors classified as PDL1-positive by the presence of immune or tumor cells showed similar biological characteristics. HER2-low TNBC showed no distinct biological phenotype when compared with HER2-zero. The majority of TNBC were classified as basal or HER2-enriched by PAM50, the latter showing significantly improved overall survival. Conclusions: Our study contributes new insights into biomarker utility for identifying suitable TNBC therapies and the intercorrelations between genomic, transcriptomic, protein, and cellular biomarkers. Additionally, our rich data resource can be used by other researchers to explore the interplay between DNA, RNA, and protein biomarkers in TNBC.
Year:
2024
Activity of INX-315 in CCNE1- amplified cancers. A, IC 50 s for palbociclib and INX-315 for cell lines shown using CellTiter Glo viability assay. All cells were treated for 6 days, n = 3 technical replicates per cell line. B, Cell cycle phase profiles of OVCAR-3 and MKN1 cells treated with INX-315. All cells were treated for 24 hours, n = 3 technical replicates per cell line; error bars are SD. C, Western blots for phosphorylated/total Rb and cyclin A2 in OVCAR3 and MKN1 cells treated with INX-315 for 24 hours. D and E, Tumor growth curves for CCNE1- amplified gastric and ovarian carcinoma models treated with INX-315 at doses shown (GA0103 n = 8 per group; GA0114 n = 8 per group; OVCAR3 n = 10 per group; OV5398 n = 10 per group; error bars represent SEM; P values calculated using two-way ANOVA. all experiments performed once). F, Western blots for phosphorylated/total Rb and cyclin A2 in tumor tissue lysates treated with control vehicle or INX-315. Samples were collected at experimental endpoint from experiments in E .
Year:
2024
Supplementary Figure 1: Characterization of INX-315. Supplementary Figure 2: Effect of INX-315 and PF-07104091 on viability of cancer and non-malignant cell lines. Supplementary Figure 3: Effect of INX-315 on cell cycle in CCNE1-amplified cancer cell lines. Supplementary Figure 4: Further characterization of the effects of INX-315 in in vitro and in vivo models of CCNE1-amplified cancer. Supplementary Figure 5: Effects of INX-315 treatment on gene expression in models of CCNE1amplified ovarian carcinoma. Supplementary Figure 6: Characterization of CDK4/6 inhibitor-resistant cell lines. Supplementary Figure 7: Response of CDK4/6 inhibitor-resistant breast cancer cells to INX-315 and PF-07104091. Supplementary Figure 8: Effects of INX-315 and PF-07104091 on CDK4/6 inhibitor-resistant breast cancer cells. Supplementary Figure 9: Impact of INX-315 +/- continued CDK4/6 inhibition in CDK4/6 inhibitorresistant breast cancer cells. Supplementary Figure 10: Characterization of a new mouse model of acquired CDK4/6 inhibitor resistance. Supplementary Figure 11: Effect of INX-315 on expression of senescence-related genes in CDK4/6 inhibitor-resistant breast cancer cells. Supplementary Figure 12: Epigenomic and transcriptomic features of INX-315 induced senescence in CDK4/6 inhibitor-resistant breast cancer. Supplementary Figure 13: Impact of INX-315 treatment of CDK4/6 inhibitor resistant breast cancer on expression of apoptosis and differentiation-related genes. Supplementary Figure 14: Impact of co-inhibition of CDK2 and CDK4/6 on cell cycle and development of CDK4/6 inhibitor resistance in breast cancer cells.
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Collaborators (4)
Courtney Kureshi
Dana-Farber Cancer Institute
Nancy Lin
Associate Professor of Medicine
Dana-Farber Cancer Institute
Lestat Ali
Dana-Farber Cancer Institute
Elizabeth Mittendorf
Harvard University
Make your next move.
Prepare your application
Review drafts before you send them.